Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

During 12-week post-treatment period, nimacimab plus semaglutide blunts weight regain compared to semaglutide alone in subset ...
FierceBiotech

Skye's shares crater as CB1 blocker fails to reduce weight in phase 2 obesity study

Skye Bioscience’s obesity candidate has failed to reduce weight in a phase 2 study, marking another setback for the CB1 inhibitor class. The biotech had been evaluating a 200-mg weekly subcutaneous ...
TipRanks on MSN

Skye Bioscience to present topline data from CBeyond on nimacimab

Skye Bioscience (SKYE) announced that it will present a late-breaking oral presentation at ObesityWeek 2025 on November 7, 2025, in Atlanta, ...
STAT

Skye’s obesity drug fails in mid-stage study

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Skye Bioscience said ...
Seeking Alpha

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data shows ...
pix11

Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide ...

Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment ...
Morningstar

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Skye’s CB1-inhibiting antibody, nimacimab, achieved significant dose-dependent weight loss of up to 16% compared to vehicle, highlighting a novel peripherally-driven mechanism for inducing weight loss ...